Evommune, Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | -100.0% | – | – | – | |
| – | +19.9% | – | – | – | -0.5% | -17.1% | +4.8% | +7.1% | – | – | |
| – | -104.8% | – | – | – | -114.3% | – | -103.3% | – | – | – | |
| – | +216.8% | -47.2% | +17.1% | -7.7% | +36.7% | +0.0% | +3.9% | -15.1% | +52.5% | – | |
| – | – | – | -26.0% | – | – | +9.9% | +94.4% | -7.5% | +27.9% | – | |
| – | +166.8% | -40.9% | +14.9% | -7.0% | +28.1% | +3.1% | +27.4% | -20.6% | +47.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | |
| – | -18.2% | – | – | – | -25.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.